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Abstract 20
Background 21
Transcription factors orchestrate the cellular response to stimuli by binding specifically to DNA and 22 activating associated genes. In the DNA damage response, the tumor suppressor p53 regulates much of 23 the transcriptional response and has been suggested to selectively regulate gene expression in different 24 contexts. However, comparison between genome-wide studies shows a large overlap between p53 bound 25 loci and thus questions this selectivity. 26
Results 27
To systematically assess the cell type specificity of p53, we directly measured its association with DNA in 28 12 p53 wild-type cell lines in response to ionizing radiation. We found that the vast majority of bound 29 sites are occupied across all cells lines uniformly. Gene expression, on the other hand showed substantial 30 variability between cell lines. The coherence of our dataset, allowed us to identify a small subset of 31 binding sites that appeared in just one or a few cell lines. We found that intrinsic chromatin accessibility 32 of a cell line explained these differential p53 binding preferences. Moreover, we were able to manipulate 33 p53 binding by altering chromatin state. 34
Conclusion 35
Our results show the limited contribution of genomic sequence to p53 binding and suggest that in vivo 36 factors including chromatin accessibility largely regulate its binding. 37 38 39 40 3 Background 41
Transcription factors (TF) are a large family of proteins that can bind to DNA and induce or repress 42 transcription of genes [1] . Substantial effort, notably through the ENCODE project, has gone into 43 generating genome wide maps of TF-DNA associations, gene expression and chromatin states. These 44 genome wide datasets have been used to identify gene regulatory networks that allow cell type and 45 stimulus-specific gene expression and led to characterization of a handful of networks, as for example in 46 the embryonic stem cells system [2, 3] . However, these studies have also revealed the complexity of gene 47 regulation and the large space of combinatorial interactions between TFs [4, 5] . Identifying the 48 mechanisms that allow tissue and stimulus-specific gene expression remains a challenge and an active 49 field of research. 50
In this work, we explored cell type and stimulus specificity of the tumor suppressing transcription factor 51 p53 at the level of DNA binding and regulation of gene expression. The major DNA damage response (DDR) 52 regulator in mammals, p53 is necessary and sufficient to impose terminal cell fates on irradiated cells. 53
Though ubiquitously expressed across human tissues, it remains unclear if p53 DNA binding is universal, 54 which could be advantageous for a critical stress response system, or shaped by the chromatin and 55 cofactor environment of different cell types and lineages. Context specific regulation of gene expression 56 by p53 has been a long standing hypothesis in the p53 field, and implies that p53 can integrate information 57 binding sites, but has limits for detection of cell line specific binding patterns due to divergent 64 experimental conditions across datasets. 65
To study how p53 binding varies across cell lines, we measured p53 DNA binding in 12 cell lines from 66 different tissue types in response to a single treatment. Indeed, we took advantage of our previous 67 characterization of these cell lines which showed a comparable acute response of p53 [16] in response to 68 ionizing radiation (IR). By treating this panel of epithelial cell lines with a dose of IR sufficient to induce 69 uniform p53 activation across cell lines, and measuring p53 binding at an early (2 hours) time-point we 70 minimized secondary effects and focused on measuring the rapid and direct binding of p53. Our approach 71 differs from the majority of p53 datasets in the literature, which use chemotherapy agents such as 72 doxorubicin or the p53 activator Nutlin3A at later time-points of 6-12 hours. This coherent set of samples 73 allowed us to rigorously explore the heterogeneity of p53 binding and identify the influence of universal 74 genomic and cell line specific chromatin factors on p53 binding and gene expression. 75
Results

p53 binding across the genome is stereotyped between cell lines and treatments 77
To study how p53 binding varies across cell lines we treated a set of 12 cell lines expressing wild type p53 78 with ionizing radiation (IR; X-Ray 4Gy) to induce p53 activity and 2 hours later cross-linked and harvested 79 each cell line for ChIP-Seq analysis. Well established p53 target genes showed robust binding in all 12 cell 80 lines ( Fig. 1A) . Overall, by pooling data from all cell lines we confidently called ~9000 p53 ChIP peaks. De 81 novo motif analysis identified a motif bearing strong similarity to previously identified p53 binding motifs 82 as the strongest single motif and also found it to be centrally enriched within peaks ( Fig. 1B) . 83
The quantitative strength of p53 binding at each genomic locus was highly conserved across the 12 cell 84 lines (Fig. 1C ). Though no strong groups of cell lines appeared by eye, hierarchical clustering correctly 85 sorted the cell lines by tissue of origin, with pairs of lung and kidney lines, and all five melanoma lines 86 clustering together (Fig. 1C ). These p53 bound regions were also similar to other published datasets 87 (average within dataset correlation 0.53, average correlation to external datasets 0.49; Fig. S1 ) and 88 consistent with previous work on p53 binding locations [10] . It was previously suggested that cancer cell 89 lines show a different p53 binding profile from non-cancerous cells [13] . We therefore compared the 12 90 cancer cell lines to an identically treated non-transformed line, RPE1. We found that p53 binding at 91 identified sites in RPE1 cells in response to IR was highly correlated with our dataset in transformed cell 92 lines ( Fig. 1D ; average R= 0.48 for correlation (RPE, Cancer Lines) vs 0.53 for correlation (Cancer, Cancer)). 93
To further explore if the apparent uniformity of p53 binding is specific to IR, we compared p53 ChIP peaks 94 in MCF7 and UACC257 cell lines treated with either IR or the p53 activator Nutlin3A. We observed 95 condition-condition correlations within each line that were stronger than any line-line correlations (Fig. 96 1E; R=0.87 or 0.88 for MCF7 and UACC257, respectively, vs R=0.73 for the maximum line-line). Thus in 97 addition to the uniformity we observe between cell lines, IR induced and pharmacologically induced p53 98 do not lead to distinct p53 function as measured by acute p53 DNA binding. 99 6 One possible explanation for why the p53 motif only had modest predictive power was the presence of 109 binding elements in the DNA that were not well accounted for by a PWM. It has been proposed, for 110 example, that flanking nucleotide identity and also general 'DNA shape' features of the binding site might 111 influence binding site choice [17, 18] . To explore if our motif analysis was simply a poor model of p53 112 binding we performed an in vitro ChIP experiment where recombinant p53 was incubated with 113 fragmented genomic, followed by immunoprecipitation and deep sequencing similarly to a recently 114 published protocol [19] . As this assay uses sheared genomic DNA with a size of ~300-600bp factors such 115 as flanking nucleotides and DNA shape should be appropriately measured. Preforming this assay, we 116 obtained a strong signal of p53 binding, recovering a consensus p53 motif (1e-2422, Fig 2C) . We observed 117 p53 binding sites, such as the one proximal to the CDKN1A/p21 promoter, that showed strong in vivo 118 binding, a strong motif, and substantial in vitro p53 binding signal ( Fig. 2D ). Whereas, other binding sites 119 such as the one contained in the first intron of MDM2 showed substantial in vivo binding, but little in vitro 120 binding (and no strong motif). Other sites such as one in the MDM4 gene showed strong in vitro binding 121 (and a strong motif), but little in vivo binding. Overall, the in vitro p53 binding signal did not show a better 122 correlation (R=0.252, P= 3.10e-127, Fig. 2E ) with in vivo p53 binding than the motif score These results 123 suggest that factors other than just DNA sequence determine p53 binding in vivo. 124 A subset of p53 binding sites is highly variable 125 7 association in the UO31 and H460 lines, and no binding in other cell lines ( Fig. 3B ). We also found 133 variability in p53 binding at the promoters of previously reported p53 target genes, ALDH3A1and EPHA2, 134 ranging from no binding in some cell lines to strong peaks in others ( Fig. 3B ). De novo motif search on this 135 set of variable peaks identified the p53 binding site as the most significantly enriched motif (HOMER, 136 p=1.0e-46), suggesting that these sites represent direct p53 binding events. 137
To determine if these highly variable binding sites had novel cell line specific functions, we assigned each 138 peak to its closest gene (with a 10 kb cutoff) and clustered the resulting 218 peaks on their p53 binding. 139
We found that most cell lines showed a few unique p53 binding sites, but without strong clustering which 140 would sort the lines into groups ( Fig. 3C ) as in Fig. 1C .
Enrichment analysis identified 141 inflammatory/chemotaxis associated genes as being enriched in these highly variable p53 bound genes. 142
The cell line LOXIMVI showed particularly strong enrichment for p53 binding to inflammatory genes 143 including IL1A, IL1B, CLL20, and CXCL1 genes, although UO31 also showed substantial binding for many of 144 these targets. We also observed, that in the estrogen receptor (ER) positive MCF7 breast cancer cell line, 145 several unique binding sites overlapped with ESR1 (estrogen receptor) binding sites, including TFF1, 146 IGFBP4, and PRLH. These results suggest that the non-uniformities in p53 binding we observed may be 147 linked to cell line specific regulatory programs. 148
p53 binding correlates with basal gene expression 149
To explore the connection between cell line specific p53 binding and gene expression, we collected RNA 150 sequencing data from each cell line in the basal, untreated state and 3 hours after IR. In contrast to the 151 uniformity of p53 binding, we saw substantially different gene expression programs in response to IR 152 across cell lines. Focusing on established p53 target genes [12] (list of target genes provided in all cell lines, MDM2 and BBC3/Puma showed variable activation despite having conserved p53 binding 156 ( Fig. 4A; Fig. 1A ). More generally, there was substantial variation in the activation of p53 targets after IR 157 ( Fig. 4B , 77 genes).However we found that, cell lines originating from the same tissue were highly 158 correlated in their gene expression response to IR. For example, the two lung cancer cell lines (A549 and 159 H460) showed a correlation of R=0.90 in their p53 target gene response to IR ( We next asked if differential p53 binding could explain this variation in IR induced gene expression in 163 different cell lines. Quantitative variation in p53 binding was essentially uncorrelated (median R=0.01) to 164 the induction of p53 target genes after IR ( Fig. 4D ). However, for the highly variable p53 bound genes 165 ( Fig. 2C ), p53 binding was correlated with basal gene expression (p=1.9e-31, t-test; Fig. 4D , E). Taken 166 together, these results suggest that while the transcriptional response of cell lines to IR is diverse, 167 relatively little of this diversity is explained by p53 binding site occupancy. Conversely, basal gene 168 expression appears to correlate with the ability of p53 to bind to a subset of genes. 169
Cell line specific chromatin accessibility accounts for variability in p53 binding sites 170
Given our observation that basal gene expression correlated with cell line specific p53 binding events, we 171 wondered if the p53 peaks specific to some cell lines can be attributed to increased chromatin accessibility 172 in these lines. It has been suggested that p53 can act as a pioneer factor with a high affinity for histone 173 occupied regions [20-22], whereas others have shown that p53 binds readily in open regions [23, 24]. Our 174 results linking basal expression of nearby genes to p53 binding suggest that the 'openness' of the genomic 175 region might influence p53 binding. To study this we focused on the LOXIMVI cell line, which showed 176 strong, and unique binding of p53 nearby inflammatory related genes and the MCF7 cell line, which 9 available. We performed a modified ATAC-Seq protocol using the MuA transposase to generate genome 179 wide maps of accessible regions in the MCF7 and LOXIMVI cell lines. We note that in this context the MuA 180 transposition occurs in a 5min 30C step, a potential advantage over the more conventional TN5 approach 181 that requires a 30min 37C incubation. Our ATAC-Seq data and ENCODE produced DNase sensitivity data 182 from MCF7 showed strong overlap with greater than 90% of ATAC-Seq peaks being DNase accessible [25] . 183
We compared our ATAC-Seq data to the p53 ChIP-Seq signal for the inflammatory genes that showed p53 184 binding in LOXIMVI but not in MCF7, and observed strong ATAC-Seq signal only in the LOXIMVI cell line 185 ( Fig. 5A) , consistent with increased accessibility at these loci leading to stronger p53 binding. Conversely, 186 GREB1, a breast cancer associated gene showed only p53 binding and ATAC-Seq sensitivity in the MCF7 187 cell line ( Fig. 5A ). Genome wide the difference in ATAC-Seq signal between the two lines accounted for 188 just over 22% of the variance in p53 binding between the two datasets (R 2 =0.225; Fig 5B) . More generally, 189
as has been observed for other transcription factors [26], combining accessibility and motif scoring allows 190 for improved prediction of DNA binding. Indeed, accessibility and motif score accounted for 13.8% and 191 20.9% of the variance in the log2(p53 ChIP-Seq peak signal) for MCF7 and LOXIMVI respectively, compared 192 to ~5% with the motif alone. We therefore conclude that chromatin accessibility favors p53 binding and 193 accounts for a substantial fraction of the cell line specific gain of p53 DNA binding sites between MCF7 194 and LOXIMVI cells. Interestingly, we also found that genome wide chromatin accessibility was negatively 195 correlated with in vitro p53 binding (R=-0.2, p=2.1e-80, MCF7 ATAC-Seq vs. in vitro binding), suggesting 196 that many strong p53 binding sites are obscured by local chromatin context. 197
To explore if, within a single cell line, perturbations to accessibility could alter p53 binding we treated 198 MCF7 cells with decitabine, a demethylase inhibitor that has been shown to broadly alter chromatin 199 structure [27] . We then treated these cells with IR and preformed p53 ChIP-Seq and ATAC-Seq on the 200 samples. Comparing p53 binding between the decitabine treated and untreated cells, we observed 201 minimal alterations in p53 binding (Fig. 5C ). Indeed, we found only one binding site, adjacent to the 202 DLGAP5 gene, that showed a substantial change in p53 binding (Fig. 5D ). This increase in p53 binding was 203 accompanied by increased accessibility (Fig. 5D ). The DLGAP5 binding site has a consensus p53 motif and 204 showed occupancy in other cell lines such as UACC62 ( As other studies have suggested, p53 DNA binding does not greatly vary across cell lines or treatments. 217 However, we did find that p53 binding could group cell lines by their tissue of origin, suggesting some 218 degree of tissue specificity. Further, we noted a modest, but significant correlation between the strength 219 of p53 binding (measured by ChIP-Seq) and the predicted strength of p53 association (using the PWM 220 model). This correlation varied across cell lines and was strongest in the pooled dataset containing all cell 221 lines. More strikingly, we observed a similar correlation when comparing genome wide in vitro association 222 of p53 with in vivo p53 binding. These results suggest that the PWM motif is a relatively accurate measure 223 of p53 binding affinity, and that flanking regions or other DNA features do not greatly improve p53 binding 224 prediction. In general, p53 binding at any given location in the genome was relatively poorly predicted by 225 either in vitro binding or motif analysis suggesting that in vivo factors greatly contribute to p53 binding 226 specificity. 227
Taking advantage of the coherence of our dataset we identified p53 binding sites that were variably 228 occupied across cell lines. This subset of peaks were nearby genes enriched for specific cellular programs, 229 most notably the inflammatory response in the melanoma LOXIMVI cell line and ER specific response in 230 the MCF7 cell line. Our ATAC-Seq data showed that this differential p53 binding could be substantially 231 explained by chromatin accessibility in the MCF7 and LOXIMVI cell lines we examined. Globally, our data 232 showed that a higher degree of chromatin accessibility favored p53 binding and is consistent with a 233 previous report showing that open chromatin can provide a permissive environment for p53 [21] as well 234
as other transcription factors such as GR [32] for example. We tested this prediction by using a 235 pharmacological agent to modify p53 chromatin state and observed increased accessibility around the 236 DLGAP5 gene that correlated with increased p53 binding. 237
Looking at gene expression of p53 bound genes, we observed no direct correlation between variation in 238 p53 binding and induction of gene expression. This suggests that although p53 binding is required for the 239 DNA damage response, the extent and mode of the IR gene expression response, is dictated by other 240 factors than p53 binding itself. We recently showed that mRNA stability of direct p53 target genes can 241 lead do differences in the timing and level of expression [33] . Further studies coupling chromatin 242 accessibility, p53 binding, post-translational modifications, and measurements of RNA synthesis and 243 degradation rates will be required to reconcile these observations and identify what features tune the 244 cellular response to DNA damage in different cellular backgrounds. 245
Conclusions 246
We found that the vast majority of p53 binding events as universal across cancerous and non-cancerous 247 cell lines, with strong quantitative agreement in binding magnitude. We further found that Nutlin3A 248 treatment resulted in a nearly identical set of p53 binding events as IR, emphasizing the universality of 249 these binding sites. These binding sites were not, however, well predicted by the local genomic sequence. 250
We identified a set of variable p53 binding events (~5%) present in only one or a handful of cell lines. 251
These binding events were often in the vicinity of transcriptionally active genes and correlated strongly 252 with cell line specific chromatin accessibility. Consistent with this, pharmacological modification of 253 chromatin state could modify p53 binding. Interestingly, we did not find a strong correlation of p53 DNA 254 binding to the transcriptional response to IR, suggesting additional layers of transcriptional control. 255
Overall we found that the acute activation and binding of p53 to DNA in response to damage is highly 256 stereotyped, with modest tuning by the chromatin environment. 257
Methods 258
General genomic analysis 259
All DNA reads were single end Illumina reads and were aligned to HG19 genome build using bowtie [34] . lines. The final set of peaks represented the consensus of HOMER (default settings) and MACS2 (using the 297 q 0.01 threshold) identified peaks, and was filtered to remove ENCODE black-list locations. The number 298 of reads within each peak region was computed from HOMER tag files using custom Matlab scripts. 299
Background regions around each peak were subtracted from peak scores to correct for high background 300
regions. The HOMER package [35] was used for de novo motif discovery. WebLogo was used to generate 301 the motif plot [41] in (Figs. 1B, 2C) for the top enriched motif. The top enriched motif (Fig. 1B) was then 302 used to re-scan and score all peaks and background regions. Background regions were generated by 303 selecting 500bp regions adjacent to either side of the peak and excluding regions that overlap with p53 304 peak regions. Clustering of peaks was accomplished using a correlation distance metric and average 305 linkage in Matlab. 306
In vitro ChIP-Seq 307
To generate recombinant p53 we in vitro transcribed/translated human p53 with a c-terminal HA tag using 308 a rabbit reticulocyte system (Promega). To generate fragmented genomic DNA we tagmented 50ng of 309 human genomic DNA from MCF7 cells using the MuSeq kit (Thermo) and amplified it using PCR Prof. Steve Elledge (Harvard Medical School), and were thawed and propagated in RPMI (GIBCO) with 5% 332 FBS. All experiments were performed in this media. All media was supplemented with 1% antibiotic and 333 antimycotic (Corning). Treatment with Nutlin3A (sigma) was at 5uM. X-ray induced DNA damage was 334 generated with a RS-2000 source (RadSource, 160KeV). MCF7 cells were treated with 2uM (5-AZA-2'-335 deoxcytidine, MP Biomedicals) for 5 days, cells were split on day 2, replated in decitabine containing 336 media. Treated and untreated cells were then further treated with IR or not as with other samples. 337
Public datasets 338
Raw fastq datasets were downloaded from the Sequence Read Archive (see supplement). These datasets 339 were all single end Illumina reads and were aligned to the HG19 genome with using the same pipeline as 340 described above for our ChIP-Seq samples, and further analyzed with HOMER to generate tag files. 341
Custom Matlab code was used to compare these datasets to our ChIP-seq data. 342
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